Literature DB >> 22879421

Characterization of vitreoretinal interface disorders using OCT in the interventional phase 3 trials of ocriplasmin.

Francis Char DeCroos1, Cynthia A Toth, Francisco A Folgar, Stephen Pakola, Sandra S Stinnett, Cynthia S Heydary, Russell Burns, Glenn J Jaffe.   

Abstract

PURPOSE: We determined the reproducibility of a novel optical coherence tomography (OCT) protocol designed to evaluate formally vitreoretinal interface abnormalities on scans obtained during two phase 3 studies of intravitreal ocriplasmin to treat symptomatic vitreomacular adhesion with or without macular hole.
METHODS: Certified technicians obtained time-domain OCT scans that included a macular thickness map (MTM), Fast MTM, and three high resolution linear scans: one 10 mm horizontal and one 10 mm vertical through the optic nerve head (ONH), and one 10 mm 5-degree-offset through the ONH and fovea. Reading Center teams graded all 3695 scans from 652 study eyes for pre-established quantitative and morphologic features. Grading reproducibility at baseline and follow-up visits was tested for presence of vitreomacular adhesion (VMA), width of vitreous adhesion (focal <1500 μm versus broad >1500 μm), presence and minimum width of full thickness macular hole (FTMH), and presence of epiretinal membrane (ERM).
RESULTS: Team grading reproducibility for VMA (kappa 0.91, 95% confidence interval [CI] 0.81-1.00), broad versus focal width of vitreous adhesion (kappa 0.87, 95% CI 0.78-0.95), FTMH (kappa 0.87, 95% CI 0.78-0.95), and ERM (kappa 0.87, 95% CI 0.78-0.95) was high. Percent agreement was 97%, 92%, 95%, and 82% for VMA, vitreous adhesion width, FTMH, and ERM, respectively. For repeated measurements of FTMH width, the intraclass correlation was 0.89 (95% CI 0.85-0.93), and the mean paired difference between grading team measurements was 34.4 μm (95% limits of agreement -149.5-218.2 μm).
CONCLUSIONS: Quantitative and morphologic vitreoretinal interface features were assessed reproducibly using a newly developed OCT scan acquisition and grading protocol. This protocol will be useful to evaluate OCT endpoints in future clinical trials, and can facilitate identification of vitreoretinal interface pathology during care of individual patients. (ClinicalTrials.gov number, NCT00781859 and NCT00798317.).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22879421     DOI: 10.1167/iovs.12-10370

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Evolution of vitreomacular adhesion to acute vitreofoveal separation with special emphasis on a traction-induced foveal pathology. A prospective study of spectral-domain optical coherence tomography.

Authors:  George P Theodossiadis; Irini P Chatziralli; Theodoros N Sergentanis; Ioannis Datseris; Panagiotis G Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-10-15       Impact factor: 3.117

2.  Foveola nonpeeling internal limiting membrane surgery to prevent inner retinal damages in early stage 2 idiopathic macula hole.

Authors:  Tzyy-Chang Ho; Chung-May Yang; Jen-Shang Huang; Chang-Hao Yang; Muh-Shy Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-03-23       Impact factor: 3.117

3.  Predicting macular hole closure with ocriplasmin based on spectral domain optical coherence tomography.

Authors:  D H W Steel; C Parkes; V T Papastavrou; P J Avery; I A El-Ghrably; M S Habib; M T Sandinha; J Smith; K P Stannard; D Vaideanu-Collins; R J Hillier
Journal:  Eye (Lond)       Date:  2016-03-11       Impact factor: 3.775

4.  Reading Center Characterization of Central Retinal Vein Occlusion Using Optical Coherence Tomography During the COPERNICUS Trial.

Authors:  Francis Char Decroos; Sandra S Stinnett; Cynthia S Heydary; Russell E Burns; Glenn J Jaffe
Journal:  Transl Vis Sci Technol       Date:  2013-12-23       Impact factor: 3.283

Review 5.  Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential.

Authors:  Su Jeong Song; William E Smiddy
Journal:  Core Evid       Date:  2014-03-21

6.  THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.

Authors:  SriniVas R Sadda; Pravin U Dugel; Victor H Gonzalez; Esmeralda Meunier; Petra Kozma
Journal:  Retina       Date:  2019-02       Impact factor: 4.256

7.  Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.

Authors:  I-Chia Liang; Kai Wang; Hsiang-Wen Chien; Szu-Yuan Lin
Journal:  Indian J Ophthalmol       Date:  2016-03       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.